ABSTRACT OF THE WEEK

Journal of veterinary internal medicine/ American College of Veterinary Internal Medicine
Volume 38 | Issue 4 (2024 Jul-Aug)

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.

J Vet Intern Med. 2024 Jul-Aug;38(4):2099 - 2119.

Stijn J M Niessen¹, Hans S Kooistra², Yaiza Forcada³, Charlotte R Bjørnvad⁴, Balazs Albrecht⁵, Franziska Roessner⁶, Esther Herberich⁷, Carla Kroh⁸

¹ Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.; ² Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.; ³ Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.; ⁴ Bjørnvad Consultancy, Vedbæk, Denmark.; ⁵ Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; ⁶ Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; ⁷ Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; ⁸ Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.

Abstract

BACKGROUND:Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia.

HYPOTHESIS:Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections.

ANIMALS:Client-owned diabetic cats (127 safety; 116 efficacy assessment).

METHODS:Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days.

RESULTS:On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference -11.8%; upper 1-sided 97.5% confidence interval, -∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin).

CONCLUSIONS AND CLINICAL IMPORTANCE:Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.

Keywords

antidiabetic; beta‐cell; compliance; feline diabetes mellitus; glucosuria; glucotoxicity; glycemic control; prospective clinical trial; sodium‐glucose cotransporter‐2 (SGLT2) inhibitor;

Article Tools:

Medline

Email to me

Grants:

Boehringer Ingelheim Animal Health

Archives Highlights:

The relationship between radiographic disc calcification score and FGF4L2 genotype in dachshunds.
Most dachshunds with 1 FGF4L2 copy have radiographic disc calcification scores that are associated with substantially lower risk of symptomatic disc disease. Radiographic disc calcification scores are similar in dachshunds with 0 and 1 FGF4L2 copies. Given the high allele frequency of FGF4L2, breeding to produce progeny with 1 FGF4L2 copy is expected to be a more achievable short-term goal for dachshund spinal health breeding programs than breeding for 0 copies. It is recommended that both K-n and FGF4L2 genotype status be considered when choosing dachshund breeding stock.

Resolution of egg binding is possible in most client-owned parrots when multiple treatment strategies are considered.
Of the 150 events that had complete follow-up, 109 (72.7%) resulted in a successful outcome. A successful outcome was observed in 44 of 133 events (33.1%) that were initially managed medically without resorting to additional treatment strategies, in 31 events (86.1%) managed with mechanical assistance, in 20 events (60.6%) managed surgically, and in 12 events (85.7%) managed with ovocentesis.

Limb amputation for feline appendicular bone tumors results in excellent recovery outcomes and high owner satisfaction with a low incidence of complications.
Time to return to walking without support was < 3 days in 69.7% of cats and 3 to 7 days in 16.7%. Activity level changes were reported as no change in 75.8% of cats. There were no behavioral changes in 92.3% of cats. Quality of life following amputation was recorded as excellent in 82.4% of cats. Owner satisfaction was reported as very satisfied, moderately satisfied, or satisfied in 98.5% of cats.

Risk Factors for Injury in Border Collies Competing in Agility Competitions.
The jump height relative to the shoulder height was associated with injury, with dogs jumping noticeably above or below shoulder height more likely to report a history of injury. Other identified risk factors included the number of weekends spent competing/year, the number of competitions at the national level, the age when starting elbow height jumps and backside jumps, the acquisition of the dog from a breeder, and the age of the handler.

Recovery of ambulation in small, nonbrachycephalic dogs after conservative management of acute thoracolumbar disk extrusion.
Forty-nine of fifty-one (96%) of deep pain-positive and 10/21 (48%) of deep pain-negative dogs recovered ambulation within the 12-week period. The median time to ambulation was 11 and 25 days for deep pain-positive and -negative dogs, respectively. Reduction in spinal cord compression varied among individuals from minimal to complete and apparently was unrelated to the recovery of ambulation.